| Document |
Document Title |
|
WO/2024/015880A2 |
The disclosure is related to a method of treating a non-genetic obesity (e.g., hypothalamic obesity) in a subject using a melanocortin-4 receptor (MC4R) agonist.
|
|
WO/2024/007859A1 |
A gambogic acid-loaded mesoporous nanoparticle, a preparation method therefor and a use thereof in cancer treatment, relating to the technical field of medicines. The gambogic acid-loaded mesoporous nanoparticle is prepared from the foll...
|
|
WO/2024/011258A2 |
Disclosed are apparatus, compositions, and methods for promoting regeneration of tissue on a subject such as a wounded, damaged, or injured appendage, or within a subject such as a wounded, damaged, or injured organ. The disclosed appara...
|
|
WO/2024/006796A2 |
The instant disclosure relates to compositions and methods that include NOX4 inhibitors as therapeutic agents capable not only of reducing fibrosis in muscle tissues of subjects having or at risk of developing a muscular dystrophy but al...
|
|
WO/2024/006292A2 |
The present disclosure relates to methods and compositions for the treatment of cancer.
|
|
WO/2024/006965A1 |
Monoclonal antibodies that specifically bind CD25, as well as conjugates of the anti-CD25 antibodies, are described. The CD25-specific monoclonal antibodies and conjugates thereof do not block binding of IL- 2 to CD25 and induce little t...
|
|
WO/2024/006804A2 |
Provided herein are methods of preventing or treating a tumor in a subject in need thereof, comprising administering to the subject a dose of a stimulator of interferon genes protein (STING) agonist, wherein the amount of the STING agoni...
|
|
WO/2024/006841A2 |
Disclosed herein among other things are methods of inducing anesthesia, sedation, and methods for treating diseases and disorders including central nervous system disorders, traumatic brain injuries, peripheral nervous system disorders, ...
|
|
WO/2024/007015A2 |
Provided herein are rearranged during transfection (RET) fusion nucleic acid molecules and RET fusion polypeptides, methods related to detecting RET fusion nucleic acid molecules and RET fusion polypeptides in cancer, as well as methods ...
|
|
WO/2024/006994A2 |
Provided herein are compositions and method for the treatment of cancer by inhibiting expression of the breast cancer gene 1 pseudogene 1 (BRCA1P1). In particular, provided herein are nucleic acid inhibitors of BRCA1P1 and methods of use...
|
|
WO/2023/245857A1 |
Disclosed in the present invention are a capsaicin-derived photosensitizer, and a preparation method therefor and the use thereof. In the photosensitizer, bodipy is used as a mother nucleus, the maximum absorption peak of bodipy red-shif...
|
|
WO/2023/248085A1 |
Systems and methods are disclosed for inducing apoptosis and treating or reducing the occurrence of at least one condition, disease, disorder, or infection in a subject. The systems and methods rely on the application of an alternating e...
|
|
WO/2023/248744A1 |
Provided is a treatment method that provides a better response rate and/or life-extending effectiveness in nonhuman mammals with cancer. Provided are: a method for treating cancer in non-human mammals, the method comprising starting tr...
|
|
WO/2023/250291A2 |
The present disclosure provides methods of treating corneal disorders with modulators of the WNT signalling pathway. More particularly, provided are treatments for cornea epithelial and/or endothelial injuries, defects, deficiencies, and...
|
|
WO/2023/250520A2 |
Cancer metastasis is the leading cause of cancer related death and involves the spreading of the tumor to distant sites throughout the body. However, there are limited therapies which can effectively target this deadly process. One prote...
|
|
WO/2023/240342A1 |
A system for obtaining imaging information, diagnosis and treatment of a subject using magneto- aerotactic-responsive bacteria; it has a processor; and memory storing program code that, when executed by the processor, cause the processor...
|
|
WO/2023/245118A2 |
Disclosed herein are MS4A4E inhibitors such as oligonucleotides that target MS4A4E. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating condi...
|
|
WO/2023/245207A2 |
The present disclosure relates to methods of selecting and/or treating a subject for treatment of a cancer with a G4-stabilizing ligand based on expression of oncogene with a G4 motif comprising GxN1-7GxN1-7 GxN1-7 GxN1-7 (SEQ ID NO: 15)...
|
|
WO/2023/245000A2 |
A method for improving stability and/or absorption of one or more biologically active agents including preparing formulations wherein a biologically active agent is dispersed using a homogenizer and/or a nanofluidizer; and optionally: i)...
|
|
WO/2023/245032A2 |
The present disclosure relates to using inhibitors of interleukin 17A (IL-17A) or its receptor for the treatment, prophylaxis or alleviation of Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) including Pediatric Autoimmune Neurops...
|
|
WO/2023/245074A2 |
Chimeric antigen receptor (CAR)-expressing neutrophils loaded with nanoparticles comprising a drug; and a method of treating cancer or other disorders in a subject comprising administering to the subject a therapeutically effective amoun...
|
|
WO/2023/245134A2 |
The present invention provides methods, systems, compositions, and strategies for the use of ARMM-mediated delivery of molecules (e.g, biological molecules, small molecules, proteins, and nucleic acids (e.g, DNA, RNA), DNA plasmids, siRN...
|
|
WO/2022/218991A9 |
Systems and methods for isolating a biological vessel from a surrounding target tissue include administering an energy-activatable substance to at least a portion of the target tissue and activating the energy-activatable substance via i...
|
|
WO/2023/239747A2 |
The expression of the ATXN2 gene can be modulated to reduce the amount of ataxin-2 protein produced by a cell. This can be accomplished by administering to the cell an effective amount of an ATXN2 modulating agent. Screening was performe...
|
|
WO/2023/237842A1 |
The present invention relates to optimised microbubbles, in particular lipid microbubbles, which can be used in the prevention and treatment of diseases or else labelling. The invention relates in particular to a lipid microbubble compri...
|
|
WO/2023/239709A2 |
Compositions and methods are provided for reducing NPM1 glutamate-glutamylation and for treating cancers characterized by overexpression of TTLL4 and/or expression of a mutant NPM1.
|
|
WO/2023/240082A2 |
The present disclosure provides a combination therapy which comprises: (i) an active agent that binds PD-1 (e.g., an anti-PD-1 antibody), (ii) an active agent that binds TIM-3 (e.g., an anti-TIM-3 antibody), and/or (iii) an active agent ...
|
|
WO/2023/240204A2 |
Methods and systems and compounds and compositions for the modulation or regulation of weight and/or inducing weight loss and other diseases and conditions in a subject are provided. Various methods of administration are described for mo...
|
|
WO/2023/240206A2 |
Compositions and methods for modulation by upregulation (up modulation) and/or downregulation (down modulation) of mitophagy are described for the treatment of mitochondrial disorders including OPA-1 related disease and Single Large Scal...
|
|
WO/2023/235810A2 |
Provided herein are systems and methods for analysis of biological samples to identify biomarkers associated with nonalcoholic fatty liver disease. For example, provided herein are molecular signatures that find use in characterizing sam...
|
|
WO/2023/235504A2 |
The present disclosure provides, among other things, methods of cancer treatment comprising steps of: a) intratumoral cell lysis, mediated by cryolysis; and b) intratumoral administration of 1) a combination of immunotherapeutic agents c...
|
|
WO/2023/235771A2 |
The disclosure provides for methods and compositions that can be used for modulating an immune response. Described are methods comprising administering an effective amount of (a) an adjuvant; and (b) one or more of bafetinib (INNO-406), ...
|
|
WO/2023/232069A1 |
An azaquinolinone compound having a structure of the following formula (I) as an enzyme inhibitor for the poly(ADP-ribose)polymerase (PARP) family, and a pharmaceutically acceptable salt, a stereoisomer, a tautomer or an N-oxide drug the...
|
|
WO/2023/230220A2 |
Disclosed herein is a method of treating a cancer by administering 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-
oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile and an immune checkpoint inhibitor. In some embodiments...
|
|
WO/2023/230610A2 |
The present disclosure provides methods and kits using certain biomarkers in predicting and monitoring post-viral syndromes (for instance, chronic fatigue syndrome (CFS) and/or long CO VID), selectively treating such syndromes, and asses...
|
|
WO/2023/230507A2 |
The present invention relates of treating a lymphocyte associated disease or condition, the method comprising administering to a subject in need thereof an effective amount of an agonist or activator of a β-catenin:Ikaros zinc finger (I...
|
|
WO/2023/230538A2 |
Provided herein are methods and kits for treating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Alzheimer's Disease Parkinson's Disease, Myasthenia Gravis, Multifocal Motor Neuropathy, Primary Lateral Sclerosis, Spina...
|
|
WO/2023/230482A2 |
Described herein relates to novel methods for determining susceptibility for infection and/or disease (e.g., pregnancy complication and/or cancer), and/or predicting severity of infection and/or disease by measuring circulating Alu RNA b...
|
|
WO/2023/230632A2 |
The subject matter disclosed herein is generally directed to methods of detecting treatment refractory cancer and treatment thereof In example embodiments, specific biomarkers expressed specifically in pancreatic cancer subtypes are disc...
|
|
WO/2023/227130A1 |
An oral hygiene apparatus, system, and use method. The oral hygiene apparatus comprises a housing (2), a battery (4), a control chip (22), a light source (23), and a light guide tip (3). The battery (4), the control chip (22) and the lig...
|
|
WO/2023/230564A2 |
The BTK-C isoform is expressed in human breast and prostate cancer cells and it plays a crucial role in epithelial cancer cell survival. BTK-C has a 34 amino acid extension to the n-terminus that facilitate it being palmitoylated on two ...
|
|
WO/2023/229368A1 |
The present application relates to a pharmaceutical composition containing a chiral nanozyme and a method for preventing or treating proliferative diseases by using same.
|
|
WO/2023/230380A2 |
Compositions and methods for the prevention and treatment of cancer and autoimmune diseases are provided which include agents which modulate the expression or function of Activins and Activin receptors. Compositions in the treatment of c...
|
|
WO/2023/225466A2 |
The present invention is generally directed to a potent therapy for SARS-CoV-2 (CoV2) disease which may involve combinations of agents. Here we describe combinations of 2, 3 or more drugs wherein the combination inhibits CoV2 replication...
|
|
WO/2023/224312A1 |
The present invention relates to fluorescent nanoparticles, a preparation method therefor and a use thereof, and provided are: a preparation method for fluorescent nanoparticles, comprising a step of mixing dopamine or dopamine analogs w...
|
|
WO/2023/223244A1 |
The present invention relates to a nanoassembly formed by the self-assembly of a compound selected from compounds of formula (Ia): [Chem. 6], R representing an alkyl group; and compounds of formula (Ib): [Chem. 7], the compound of formul...
|
|
WO/2023/225640A2 |
Epilepsy is one of the most common neurological disorders. However, there are currently no drugs available to prevent and/or reduce the development of said disorder. Thus, compositions and methods described herein prevent and/or arrest t...
|
|
WO/2023/225477A2 |
Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present inven...
|
|
WO/2023/225662A2 |
The present disclosure provides proteolysis targeting chimeras-based scalable CID (PROTAC-CID) system that repurpose PROTACs for inducible, orthogonal, and multiplex transcriptional activation. When coupled with multi-layer genetic circu...
|
|
WO/2023/223962A1 |
Provided is a surface-modified nanodiamond that can selectively accumulate a sufficient amount of boron atoms in cancer tissues or cancer cells and can efficiently kill or injure cancer cells. The surface-modified nanodiamond of the pr...
|
